Orthobiologics market seen reaching $13.41 billion by 2035

Market Research Future projects the global orthobiologics market will grow from $7.61 billion in 2026 to $13.41 billion by 2035, driven by aging populations, osteoarthritis demand, regulatory easing and more outpatient orthopedic procedures. The forecast points to stronger demand for biologic joint-preservation and spine products across hospitals, ambulatory centers and major regional markets.

Why it matters: - Orthobiologics are moving from a niche orthopedic category to a core part of regenerative, sports medicine and value-based care. - The forecasted rise to $13.41 billion by 2035 signals more demand for biologic treatments that can delay or reduce joint replacement and support spinal surgery. - Growth is tied to aging populations, rising osteoarthritis cases and the shift of musculoskeletal care to lower-cost outpatient settings.

What happened: - Market Research Future estimated the global orthobiologics market at $7.15 billion in 2025. - The firm projects the market will reach $7.61 billion in 2026 and $13.41 billion by 2035. - The forecast implies a 6.5% compound annual growth rate from 2026 through 2035. - The report was released July 6, 2026. - A free sample is available. - The full report and customization request are also available.

The details: - Osteoarthritis affects about 7% of the global population and about 15% of adults over 60, according to Lancet Rheumatology data published in 2023. - The World Health Organization projects osteoarthritis prevalence will rise 75% by 2050 and affect 528 million people by 2030. - The U.S. Food and Drug Administration cleared 18 new platelet-rich plasma preparation devices through its 510(k) pathway in 2024. - The National Institutes of Health allocated more than $320 million to musculoskeletal regenerative research grants in fiscal 2024. - China’s 14th Five-Year Plan for Healthcare set aside $48 billion for hospital construction and equipment modernization. - Viscosupplementation products led the market in 2025 with about 46.1% revenue share. - Platelet-rich plasma was the fastest-growing product class, projected at 7.6% CAGR from 2026 to 2035. - Bone grafts and substitutes were valued at $1.49 billion in 2025. - Bone morphogenetic proteins held 11.3% share in 2025. - Cell-based therapies are projected to grow at 8.9% CAGR. - Spinal fusion was the largest application in 2025, at 57.0% of revenue, or about $4.08 billion. - Osteoarthritis and joint degeneration was the fastest-growing application, at 10.3% CAGR. - Hospitals and orthopedic centers held about 67.4% share in 2025, or about $4.82 billion. - Ambulatory surgical centers were the fastest-growing end-user segment, at 8.8% CAGR. - Surgical procedures accounted for about 58% of demand in 2025. - Local injection was the fastest-growing delivery method, at 9.2% CAGR. - North America led the market with about 46.2% share in 2025. - The United States generated about 82.4% of North American revenue. - Europe was the second-largest region with $1.84 billion in 2025. - Asia-Pacific was the fastest-growing region, with 12.1% CAGR from 2026 to 2035. - The Middle East and Africa region is projected to grow at 7.8% CAGR. - The market was described as moderately concentrated, with the top five suppliers holding roughly 48% to 55% of global revenue. - Medtronic, Stryker, Zimmer Biomet, Johnson & Johnson’s DePuy Synthes unit and Arthrex were listed as key companies.

Between the lines: - The forecast suggests reimbursement, regulation and outpatient delivery are becoming as important as clinical demand in shaping orthobiologics growth. - The strongest opportunities appear to be in products that fit same-day procedures, such as PRP and viscosupplements, and in spine-related grafting products with established hospital reimbursement. - The report also signals a gradual shift from a procedure-driven market to a data-driven one, as real-world outcomes registries and AI-based treatment selection become more important. - Some of the report’s forward-looking claims, including 3D bioprinting and digital-therapy combinations, remain pre-commercial and should be treated as directional rather than settled market outcomes.

What's next: - The report expects real-world evidence registries to become more important by 2030 for payer negotiations, label expansion and provider analytics. - It also expects 3D bioprinting and next-generation scaffolds to open a potential $800 million incremental segment in the early 2030s. - Combination protocols that pair biologic injections with app-based rehabilitation and wearable monitoring could widen the patient base if clinical results continue to improve. - AI tools that analyze imaging, comorbidities and healing biomarkers are moving through clinical validation and may help reduce therapy failure rates by 15% to 20%.

The bottom line: - Orthobiologics are set for steady expansion through 2035, with aging populations, osteoarthritis burden and outpatient orthopedic care creating a durable growth path.